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Abstract
Background: Kidney disease is a serious manifestation of systemic amyloidosis and a major cause of morbidity and
mortality. Tuberculosis (TB) occurs up to 27 times more commonly in human immunodeficiency virus (HIV) infected
patients and is also an important cause of renal amyloid; there are however no reports of renal amyloidosis in
South Africa in the HIV era.
Methods: This was a retrospective record review of cases of amyloidosis diagnosed on renal biopsies at our tertiary
referral hospital between January 1985 and December 2016.
Results: Forty-six cases of amyloidosis were identified over the study period. The calculated biopsy prevalence was
1.38 per 100 non-transplant renal biopsies (95% Confidence Interval 1.02–1.86). AL amyloidosis was identified in 26
(57%) cases and AA in 20 (43%). The median age at presentation was 51 years and 52% of cases were female.
Patients with AA amyloidosis were significantly younger compared to their AL counterparts (age 42 years vs. 58
years, p = < 0.001) and were all significantly non-white. The main clinical presentation was nephrotic syndrome
(85%) and 52% of cases also had a serum creatinine value of greater than 120 μmol/L. Of the 20 cases of AA
amyloidosis, 12 (60%) were associated with tuberculosis. HIV infection was noted in only two (10%) of the 20 AA
cases. Median survival after diagnosis was 2 months.
Conclusion: Amyloidosis is a rare cause of kidney disease and typically presents with nephrotic syndrome. A similar
number of AA and AL types were observed, and outcomes are worse in cases of AA amyloid. While TB remains the
major underlying disease in this type, HIV infection was infrequent in cases of AA renal amyloidosis.
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Background
Renal manifestation of systemic amyloidosis carries a
significant morbidity and mortality, and is most fre-
quently seen either in the setting of chronic inflamma-
tion (AA amyloidosis), or plasma cell dyscrasias (AL
amyloidosis) [1–5]. Without treatment, amyloidosis as-
sociated kidney disease progresses rapidly to end-stage
renal disease (ESRD). A recent study reported dialysis
dependence within 18months of diagnosis of AA amyl-
oidosis and mean patient survival of 52.9 months, whilst
these outcomes were 36.3 months and 50months re-
spectively in AL amyloid [4, 6].
Marked differences in the epidemiological patterns
of amyloidosis are seen between different countries,
highlighting the importance of local data [2, 7–9]. AL
amyloidosis is more prevalent in developed countries,
whilst AA amyloidosis is more common in the devel-
oping world [2, 7, 8, 10]. The developmental status of
a particular country, its prevalence of infectious dis-
eases, as well as public health measures implemented
to control chronic infections are dynamic factors in-
fluencing the prevalence of secondary (AA) amyloid-
osis over time [5, 11, 12]. Tuberculosis (TB) is a
common underlying disease in AA amyloidosis, par-
ticularly in developing countries [2, 7, 9]. Underlying
human immunodeficiency virus (HIV) infection in-
creases the risk of TB 6 to 27 times compared to those
that are not infected [13]. South Africa has amongst
the highest rates of both TB and HIV infection in the
world; the incident rate of TB was 781 cases per 100,
000 population in 2016 and the estimated HIV preva-
lence rate was 12.57% of the total population [13, 14].
The immunocompromised state rendered by HIV in-
creases the risk of TB disease substantially, with a TB/
HIV co-infection rate in South Africa of 70% [15].
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Amyloidosis is generally an uncommon histological
finding on renal biopsies of HIV infected patients.
Gerntholz et al. [16] identified no cases of amyloidosis
among 99 patients and Wearne and Okpechi [17] a sin-
gle one among 221 South African patients; Wyatt et al.
[18] reported one case of amyloidosis among 89 Ameri-
can and as did Nebuloni et al. [19] in 73 Italian subjects.
The cases of amyloidosis and HIV infection that have
been reported are predominantly in intravenous drug
users (IVDUs) [20–22]. Data from the pre-HIV era in
South Africa suggest that AA amyloidosis is the most
common type of amyloidosis seen and that TB infection
is the most frequently associated risk factor [2].
We reviewed all the cases of renal amyloidosis at our
institution in the context of the HIV epidemic currently
prevailing in South Africa.
Methods
Study design
We conducted a retrospective review of consecutive
cases of renal amyloidosis.
Setting and study population
Renal biopsies performed at Tygerberg Academic Hos-
pital between 01 January 1985 and 31 December 2016
were identified using the kidney biopsy register. This
register served as the sampling frame and cases of defini-
tive or possible amyloidosis were extracted from this
source. Tygerberg Academic Hospital is a tertiary refer-
ral hospital that serves about one-half of the population
of Western Cape, which was estimated at six and a half
million in 2017 [14].
Participants
All participants aged 13 years and older at renal biopsy,
who had a histological diagnosis of renal amyloidosis, as
defined by renal biopsy with either apple green birefrin-
gence on Congo Red stain and/or amyloid fibrils de-
tected on electron microscopy, were included.
Sampling technique
Records from the renal biopsy register were reviewed over
the 32-year period. All cases diagnosed as definite or pos-
sible amyloidosis were evaluated. All renal pathology has
been reviewed by a single experienced renal pathologist
(WDB). All renal tissue was collected by percutaneous bi-
opsy and evaluated by light microscopy, immunofluores-
cence and electron microscopy. Renal biopsy material was
received fresh and unfixed, evaluated and divided under a
dissecting microscope to provide optimal numbers of glom-
eruli for light and electron microscopy as well as immuno-
fluorescent studies. The ultrastructural material was then
fixed in 2.5% glutaraldehyde in 0.1M phosphate buffer,
while the light microscopy material was fixed in buffered
formalin. Material for immunofluorescence was frozen,
cryostat sections cut and labeled for IgA, IgG, IgM and C3.
Electron microscopy (EM) specimens were post-fixed in os-
mium tetroxide embedded in Spurr’s resin.
For light microscopy, serial two-to-three micron sec-
tions were stained with hematoxylin and eosin and other
special stains, including Congo Red (Fig. 1).
For all this period, immunohistochemistry for AA
amyloidosis was available and performed routinely. Test-
ing for kappa and lambda light chains was carried out
via immunohistochemistry for most of the study period,
with a few recent cases employing immunofluorescence.
The diagnosis of amyloidosis was confirmed by a
positive Congo red staining examined with apple-
green birefringence under polarized light. Typical
electron microscopic features of randomly disposed,
rigid, nonbranching and variably long fibrils were also
considered diagnostic.
Case histories were obtained from hospital records
and supplemented by relevant laboratory databases. All
the diagnoses listed in clinical notes, evidence of treat-
ment of a specific condition (e.g. TB treatment) or
pathological confirmation of a disease prior to, as well as
6 months after the date of biopsy findings of amyloid-
osis, were recorded. Data were analysed and attempts
made to determine the type of amyloidosis present if not
explicitly stated in the clinical record. This was done
considering the clinical history, immunohistochemistry
on biopsy, as well as further testing specifically for
plasma cell dyscrasias. If a case was indeterminate, it was
documented as such. Survival was determined from
medical records, hospital registry data or national mor-
tality records.
Demographic data included were age at renal biopsy,
ethnicity and gender; clinical data related to presentation
and the indication for biopsy; laboratory data were de-
gree of proteinuria (either by 24-h urine collection or es-
timated from spot urine protein: creatinine ratio), serum
creatinine, serum albumin and serum cholesterol as well
as HIV antibody testing using ELISA techniques. When
multiple entries for the same variable were found, data
were captured with preference given in order to the first
set of values obtained 1 month before biopsy (presum-
ably taken on admission), the values recorded on the
histology report, and lastly any value found from 1
month pre-biopsy to 6 months post biopsy. Case records
of the 46 patients were supplemented with additional la-
boratory data available for 33 of the cases (72%).
Statistical considerations and sample size
The sample size was limited by the number of cases identi-
fied over the study period. The prevalence of amyloidosis
on renal biopsy was calculated by dividing the number of
cases of amyloidosis by the total number of adult non-
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transplant biopsies performed over the study period. IBM
SPSS version 23 (IBM Corp. Released 2015. IBM SPSS Sta-
tistics for Windows, Version 23.0. Armonk, NY: IBM
Corp.) was used to analyse the data. Survival was estimated
using Kaplan-Meier analysis. Values are reported as
medians with inter-quartile ranges (IQR). Non-parametric
Mann Whitney tests were used to compare non-normally
distributed continuous variables between the two types of
amyloidosis. Pearson’s chi-square or Fisher’s exact tests
were used compare categorical variables between the types.
A p value < 0.05 was considered statistically significant.
Results
Over the 32-year period, 3329 non-transplant renal bi-
opsies were performed and 48 (1.4%) cases of amyloid-
osis were identified. One patient with amyloidosis on
three separate renal biopsies was only counted once.
The prevalence of amyloidosis on renal biopsy over the
32-year period was 1.38 per 100 non-transplant renal bi-
opsies. There was a trend to a decline in the biopsy
prevalence of all types of amyloidosis over the 32-year
period, mainly due to fewer AA cases noted over this
time.
The epidemiology, presenting features, laboratory fea-
tures and survival outcomes are shown (Table 1). The
median age at presentation was 51 years (range 21 to 85)
and 24 of the 46 patients (52%) were female. The neph-
rotic syndrome was the commonest presentation in 39
(85%) patients, followed by renal failure (serum creatin-
ine > 120 μmol/L) in 24 (52%).
The cases were classified as AL type (26 cases, 57%) and
AA (20 cases, 44%). Screening tests to exclude AL amyloid-
osis (serum or urine protein electrophoresis) were per-
formed in 45% of those with AA amyloidosis. Bone marrow
examination was performed in 24 of the 26 AL cases. AA
amyloidosis patients were younger (median age 42 years,
IQR 31–51 years) compared to those with AL disease (me-
dian age 59 years, IQR 50 to 66 years). None of the patients
with AA amyloid were white; by contrast 7 (27%) of AL
cases were white.
Immunohistochemistry of the biopsy specimen identi-
fied 18 (90%) cases with the final clinico-histopathological
diagnosis of AA amyloidosis. The remaining two (10%)
cases were presumed to be of the AA type as the immuno-
histochemical staining was indeterminate; one had active
pulmonary tuberculosis whilst the second had infective
endocarditis and HIV infection, with no monoclonal peak
detected in the urine or serum. Only one patient identified
as having AA on immunohistochemistry of the renal spe-
cimen was found to have a clinico-histopathological diag-
nosis of AL after subsequent investigations. 13 (50%) cases
with the final clinico-histopathological diagnosis of AL
amyloidosis were indeterminate on immunohistochemis-
try or fluorescence, with 11 cases (42%) being correctly
identified. This diagnostic uncertainty was primarily due
to high background staining, likely from contaminating
serum proteins [23]. The remaining cases all had a detect-
able monoclonal peak in serum, urine or bone marrow
Fig. 1 Histology of renal amyloidosis. a H&E stain shows extensive
effacement of the glomerular architecture by amorphous amyloid. b
The involvement of glomeruli by AA amyloid are revealed by
immunohistochemistry using antibody specific for amyloid A
protein. c Electron micrograph shows random alignment of amyloid
fibrils in the subepithelial zone of a glomerular capillary
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analysis and usually no associated predisposing cause for
AA amyloidosis on clinical grounds.
Serum albumin was significantly lower in cases with
AA amyloidosis (18 vs. 23.5 g/L, p = 0.03) and median
serum creatinine as well as magnitude of proteinuria
was higher in AA compared to AL amyloidosis (serum
creatinine 276 vs. 88 μmol/L, proteinuria 9.7 vs. 6.12 g/
24 h) but failed to attain statistical significance.
Of the 20 cases of AA amyloidosis, 12 (60%) were
associated with pulmonary TB. Of these 12, three
also had bronchiectasis and one patient had active
TB as well two other chronic infections (bronchiec-
tasis and bilharzia). Two cases of AA amyloid had
no known associations, although both patients had a
history of pulmonary TB 10 to 15 years prior to the
diagnosis of amyloidosis; the remaining associated
conditions in AA amyloidosis are shown (Fig. 2).
None of the cases of AA amyloidosis were known
intravenous drug users (IVDUs) or had hepatitis B
or C infection.
Of the 26 patients with AL amyloid, 12 (42.2%) were
diagnosed with multiple myeloma and were treated with
steroids, and either melphalan or cyclophosphamide. Of
the remaining 14 patients with AL amyloid four received
melphalan and steroids; the remainder received no spe-
cific therapy. In patients with AA amyloidosis treatment
was primarily of the underlying disease as identified.
Both HIV-infected patients were anti-retroviral therapy
naïve at presentation.
Other organ involvement occurred mostly in pa-
tients with AL amyloid: a single patient had amyloid
deposits on colonic biopsy and four on the bone mar-
row biopsy; single patients with AL amyloid had hepa-
tosplenomegaly, macroglossia; and suspicious thyroid
lesions on radioisotope scan; two patients with mul-
tiple myeloma were diagnosed with carpal tunnel syn-
drome and three patients had echocardiographic
findings suspicious of cardiac involvement. Interest-
ingly, none of the patients with AA amyloid mani-
fested systemic disease at presentation.
Table 1 Characteristics of 46 cases of renal amyloidosis
AA AL p value Total
Number of cases, n (%) 20 (43) 26 (57) 46 (100)
Age (years) at diagnosis, median (IQR) 42 (31–51) 58 (50–66) < 0.001 51 (41–62)
Sex, n (%) 0.74
Male 9 (45) 13 (50) 22 (48)
Female 11 (55) 13 (50) 24 (52)
Ethnicity, n (%) 0.03
African 10 (50) 7 (27) 17 (37)
White 0 7 (27) 7 (15)
Mixed race 10 (50) 12 (46) 22 (48)
Presentation, n (%) 0.59
Nephrotic syndrome 8 (40) 14 (54) 22 (48)
Nephrotic syndrome and renal failure
(serum creatinine > 120 μmol/L)
9 (45) 8 (31) 17 (37)
Renal failure without nephrotic
syndrome
3 (15) 4 (15) 7 (15)
Laboratory Features, median (IQR)
Serum creatinine (μmol/L) 276 (68.5–882.5) 88.5 (82–244) 0.52 172 (81–385)
Degree of proteinuria (g/day) 9.7 (5.1–17.6) 6.2 (4.8–8.2) 0.19 6.76 (4.9–12.0)
Serum albumin (g/L) 18 (16.0–20) 23.5 (18–31) 0.03 19 (16–29)
Serum total cholesterol (mmol/L)) 6.12 (5.14–7.8) 8.80 (6.60–12.17) 0.01 7.45 (5.9–11.6)
HIV Status, n (%) 0.15
Positive 2 (10) 0 (0) 2 (4)
Negative 15 (75) 18 (69) 33 (72)
Unknown 3 (15) 8 (31) 11 (24%)
Outcomes
Survival after diagnosis (months),
median (IQR)
1 (0.75–1.25) 9 (1.5–15) 0.02 2 (1–10)
Abbreviations: AA Secondary amyloidosis, AL Primary amyloidosis, HIV Human immunodeficiency virus, IQR interquartile range
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HIV status was known in 35 (76%) patients with no
test results available before 1992. HIV infection was
noted in only two patients (4%); both cases were of the
AA type. One of these patients had infective endocarditis
and the other had no identifiable association although
the patient did have pulmonary TB 14 years prior to bi-
opsy. By comparison, in the total 3329 renal biopsies
done over the study period, 481 biopsies were in patients
with confirmed HIV, with a total biopsy prevalence for
HIV of 14.4%. Analysis of data exclusively in the period
after the introduction of HIV testing in 1992 yields a bi-
opsy prevalence of HIV of 5% in the amyloid cohort, and
17% in the overall biopsy cohort.
Survival data were available for 25 (54%) patients
(Fig. 3). The median survival was 2 months after
diagnosis with a range of 0 to 249 months. A signifi-
cantly worse outcome was found in cases of AA
amyloidosis, with a median survival of 1 month after
diagnosis as compared to 9 months in AL amyloid-
osis (p = 0.02).
Fig. 2 Causes of AA and AL amyloidosis
Fig. 3 Kaplan-Meier estimate of survival of patients with amyloid (N = 25)
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Discussion
Amyloidosis is a rare cause of kidney disease accounting for
less than 2 % of all biopsied patients and is most commonly
associated with TB in the South African setting. It is most
likely to present with nephrotic syndrome. A similar num-
ber of AA and AL cases were observed and outcomes were
poor. AA amyloidosis patients were noted to be younger
compared to AL patients, usually had an identifiable disease
associated with amyloidosis established on presentation and
were all African or mixed ethnicity. HIV infection in our
community appeared not to have a discernible impact on
the prevalence of amyloidosis in South Africa in our study.
These observations are consistent with other studies.
The high proportion of TB associated cases in AA amyl-
oidosis (60%) was higher than the 40% reported by Mody
in 1984. This likely represents the increasing incidence
of TB over the past three decades [24].
The total number of AL cases slightly exceeds those
of AA which is unusual for a developing country.
This difference was small but difficult to explain, es-
pecially considering the high levels of TB noted in
South Africa. A comparison of the associated diseases
of AA amyloidosis in different regions of the world is
shown (Fig. 4).
Based on the high prevalence of HIV in our setting of
12.6%, we had expected to see many more cases with
HIV (Fig. 5). A possible explanation for this is sampling
bias. The clinical presentation of HIV associated ne-
phropathy (HIVAN) with nephrotic range proteinuria,
renal failure and large kidneys on ultrasound is very
similar to that of amyloidosis. However, the standard
practice of our institution is to perform a renal biopsy in
all cases of suspected HIVAN if not contra-indicated,
making this explanation unlikely.
HIV infection has been associated with both AA and
AL amyloidosis in case reports [21, 22, 26–28]. Most
cases of AA amyloidosis have been reported in IVDUs,
fewer cases with visceral leishmaniasis and multicentric
Castleman’s disease, and to our knowledge, only 1 case
report exists of HIV, amyloidosis and presumed TB
coexisting in a known IVDU [20–22, 29, 30].
Of the two patients in our study with HIV, one had in-
fective endocarditis which was thought to be directly as-
sociated with amyloidosis, whilst the other had no other
clinical manifestation apart from HIV infection which
could be directly associated with amyloidosis. None of
the cases in our series were known IVDUs. Based on a
high estimated prevalence of IVDUs in our population
[31], this is likely a result of sampling bias in a single
centre study.
The association between amyloidosis and HIV is
plausible, as higher levels of serum amyloid A (SAA)
protein - the acute phase reactant protein from which
amyloid fibrils are derived in AA amyloidosis - has been
documented in HIV positive individuals [26, 32, 33].
However, substance abuse without HIV infection has
also been associated with higher levels of SAA. Samik-
kannu et al. [28] reported higher levels of SAA in
IVDUs, alcoholics and those abusing methamphet-
amines, independent of underlying HIV infection.
Case series of amyloidosis have revealed discrepant
prevalence of HIV in renal amyloidosis. Jung et al. [21]
found 12 cases of renal amyloidosis in 24 renal biopsies
of IVDUs in a single metropolitan area in Germany, with
a significantly higher HIV infection rate (8 cases) in
those with amyloidosis than those without amyloidosis
(2 cases of HIV). This high percentage of amyloidosis
found in this cohort of IVDUs (50% of cases) is much
higher than reported in other studies. A Portuguese
study of 19 IVDUs, of 3 who also had HIV, reported
only a single case of amyloidosis. Similar results were
found in an American study of 14 HIV and hepatitis C
co-infected IVDUs, where no cases of amyloidosis were
found [34, 35].
Fig. 4 Proportion of diseases associated with AA amyloidosis in different countries [2, 7–9]
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This discrepancy in the prevalence of HIV in amyloid-
osis suggests that other confounding factors may be
present. Miranda et al. [20] postulate that these discrep-
ancies are largely based on geographical peculiarities and
point to skin and soft tissue infection in IVDUs being
the driving factor for amyloid deposition, not HIV or
hepatitis B or C. Our data, with a low HIV infection rate
and no IVDU cases, would support this theory.
Similar to HIV and rather unsurprisingly, TB has also
been found to have high levels of SAA [36]. However,
we noted no cases of TB (the major predisposition for
AA amyloidosis in our study) and HIV co-infection, a
finding which is difficult to explain considering the high
levels of SAA reported in both conditions together with
the 70% HIV/TB co-infection rate found in South Africa.
These findings may be corroborated from reviewing the
literature, as no case has been described of definitive TB
alone causing AA amyloidosis in an HIV infected
individual.
Thus, the association between amyloidosis and HIV infec-
tion is complex and not well understood. Husebekk et al.
[37] suggested in 1986 that amyloidosis may not be found in
HIV as its course progressed rapidly to demise. However,
survival of patients with HIV has improved dramatically
since then and this factor alone cannot explain the low fre-
quency of HIV infection amongst our cases. We put forward
two novel suggestions about the link between HIV and
amyloidosis: firstly that AA amyloidosis may protect an indi-
vidual from HIV infection as high levels of SAA usually seen
in AA amyloidosis have been found to confer some resist-
ance to HIV infection after exposure to the virus [38, 39];
secondly that HIV may even be protective against amyloid-
osis through impairment of the complex process of fibrillo-
genesis [40]. Immune dysregulation in HIV, manifesting
with alterations in CD4+ T helper cell subsets’ function and
quantity, may be a mechanism of this impairment of fibrillo-
genesis [41]. No direct evidence exists to support the second
theory and further studies are needed to clarify this
association.
The high mortality rate in our patient reflects the ad-
vanced state of disease at presentation due to delay in
help seeking and/or diagnosis. The exact cause of death
was not always known. The survival of a single patient
for 249 months in AA amyloidosis due to pulmonary TB
suggests that adequate treatment in certain individuals
may induce a remission in this disease, but factors re-
lated to this could not be identified in our study.
The strengths of this study lie in the extended period
over which data were available, the use of various specia-
lised tests to confirm the diagnosis and type of amyloid-
osis (electron microscopy and immunohistochemistry on
biopsy) and the various databases which were searched
to obtain and confirm data over this period. The high
prevalence of HIV in our setting provided a unique en-
vironment to observe the association between HIV and
amyloidosis. The weaknesses are primarily related to the
nature of retrospective case series which are reliant on
completeness of data and observations made at the time
of presentation. The inability to test for genetic causes of
renal amyloidosis may have led to a misclassification of
the type of amyloidosis, although these hereditary causes
are uncommon [42]. Due to the small numbers in our
study, further statistical analysis to substantiate the im-
pact of HIV on amyloidosis was limited.
Conclusion
Amyloidosis is a rare cause of kidney disease in our set-
ting with poor outcomes. A similar number of AA and
Fig. 5 Comparison of HIV prevalence in populations (a and b) [14, 25] and within our biopsy cohort (c and d)
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AL cases were observed, and a nephrotic presentation is
characteristic. TB is the usual association in AA amyl-
oidosis and highlights its burden on health in South Af-
rica. HIV was not found to have a discernible impact in
the prevalence of amyloidosis in South Africa in our
study and our hypothesis that HIV infection and amyl-
oidosis may be mutually protective needs further study.
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